Neurolixis, Inc.

Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Steven A.

Neurolixis Inc. announced that it had been awarded a second research grant by the Rett Syndrome Research Trust (RSRT) to support the development of its novel serotonin 5-HT1A receptor agonist, NLX-101.

Neurolixis, Inc., a private biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, will present the latest preclinical data on its drug candidate, NLX-112, at the 19th International Congress of...

Neurolixis SAS, the French subsidiary of Neurolixis Inc., a privately held biotechnology company, announced today that it had been awarded 'Jeune Entreprise Innovante' (JEI; literally 'Young Innovative Company') status by the French Public Finances...

Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Mark Corrigan, M.D. to its Advisory Board. Dr.

Dana Point, CA, April 21, 2015 -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that Dr. Mark A.

Neurolixis today announced that it had been selected by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to be showcased in its Partnering Program.

Strategic Collaboration Focused On Generation of Novel CNS Therapeutics

Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that NLX-101, its selective serotonin 5-HT1A receptor ‘biased agonist’ has been granted Orphan Medicinal...

San Diego, CA, September 23, 2013 -- Neurolixis, Inc. today announced that it has licensed the worldwide development and commercialization rights to two clinical compounds from Pierre Fabre Medicament.